Pfizer Sells $3.3 Billion Stake in Sensodyne-Maker Haleon

Pfizer sells its $3.3 billion investment in Haleon, the company known for producing Sensodyne. This decision marks a significant reduction in Pfizer’s holdings in the consumer healthcare sector. The move comes as Pfizer continues to refocus on its core pharmaceutical business, particularly in the wake of its successful COVID-19 vaccine and treatment developments. By divesting from Haleon, Pfizer aims to streamline its operations and allocate resources more effectively. Haleon, which has a strong presence in the oral care market, will proceed with its current strategies as it continues to grow independently.